A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

Kose M. F., Sufliarsky J., Beslija S., Saip P., Tulunay G., Krejcy K., ...More

GYNECOLOGIC ONCOLOGY, vol.96, no.2, pp.374-380, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 96 Issue: 2
  • Publication Date: 2005
  • Doi Number: 10.1016/j.ygyno.2004.10.011
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.374-380
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Objectives. Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study.